Up to 3,500 first time mums are due to take part in a study led by Cambridge researchers to understand why some will develop pre-eclampsia and placental complications during pregnancy and whether it effects their long-term health.
Cambridge scientists have grown beating heart cells in the lab and shown how they are vulnerable to SARS-CoV-2 infection. In a study published in Communications Biology, they used this system to show that an experimental peptide drug called DX600 can prevent the virus entering the heart cells.
Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology.
Scientists at AstraZeneca, a global biopharmaceutical company, have been working with Cambridge University for more than two decades. What are the secrets of their success?
When a drug fails late on in clinical trials it’s a major setback for launching new medicines. It can cost millions, even billions, of research and development funds. Now, an ‘adaptive’ approach to clinical trials and a genetic tool for predicting success are increasing the odds of picking a winner.
Researchers at the University of Cambridge, in collaboration with the University of Edinburgh, have shown how a radioactive agent developed in the 1960s to detect bone cancer can be re-purposed to highlight the build-up of unstable calcium deposits in arteries, a process that can cause heart attack and stroke.
© 2024 University of Cambridge